Mirum Pharmaceuticals, Inc. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
Standard Sarbanes-Oxley certification exhibits (31.1, 31.2, 32.1, 32.2) signed by CEO Christopher Peetz and CFO Eric Bjerkholt on August 5, 2026, for the quarter ended June 30, 2026. Certifiers attest that the report contains no material misstatements, financial statements fairly present the company's condition, and disclosure controls and internal controls over financial reporting are effective. No material weaknesses or fraud disclosures identified.
Why this rating
Routine SOX certification exhibits; standard regulatory requirement. No substantive business developments, financial data, or control issues disclosed.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.